An estimated 100 million Americans have some degree of fatty liver disease, and until very recently, not a single drug was approved to treat it. Now a team at the Medical University of South Carolina (MUSC) has shown that formoterol, a cheap generic bronchodilator found in asthma and COPD inhalers for more than 20 years, reversed established liver steatosis in obese mice in just four weeks. The results, published in npj Metabolic Health and Disease, have energized a push to test the drug in people. A human pilot trial of formoterol in diabetic kidney disease is already recruiting at MUSC, and the researchers have signaled plans to expand toward liver-specific endpoints, potentially within the year.
If the effect holds up in patients, formoterol could become one of the least expensive entries in a treatment space that, as of mid-2026, has essentially zero approved options on pharmacy shelves.
What the mouse studies actually showed
The core experiment was straightforward. Mice were fed a high-fat diet long enough to develop confirmed liver steatosis, the hallmark fat buildup of non-alcoholic fatty liver disease (NAFLD). One group then received formoterol; a control group received a vehicle. After four weeks, the treated mice showed dramatic improvements in NAFLD Activity Score histology, measurable shifts in liver lipid classes on thin-layer chromatography, and increased markers of mitochondrial biogenesis.
That last detail is central to the proposed mechanism. Mitochondrial dysfunction is widely considered a driver of fat accumulation inside liver cells. By stimulating the renewal of those organelles, formoterol appears to help the liver burn off stored fat rather than simply slowing new deposits. The researchers described the outcome as reversal of steatosis, not merely prevention, a distinction that matters because most patients are diagnosed after fat has already built up.
The liver discovery actually grew out of kidney work at the same institution. A separate study, published in the American Journal of Physiology, demonstrated that formoterol reversed diabetic renal injury in mouse models, including improvements in albuminuria and kidney ultrastructure. While investigating those kidney effects, the team noticed parallel improvements in liver tissue, prompting the dedicated liver experiments that followed.
A human trial is already underway, but not for the liver yet
The federal clinical trials registry lists NCT07022418, titled “Formoterol in Diabetes,” as a prospective, randomized pilot study of formoterol fumarate plus standard of care in patients with diabetic kidney disease. MUSC sponsors the trial, with nephrologist Joshua Lipschutz as the responsible investigator. As of May 2026, the study is actively recruiting.
That trial targets kidney disease, not fatty liver. But the existing regulatory groundwork, safety monitoring, and dosing experience it generates give the team a running start toward designing a liver-focused study. MUSC’s institutional communications have described ambitions to expand testing toward liver endpoints, though no dedicated MASH or steatosis trial appears in any public registry yet, and no FDA investigational new drug application for that indication has surfaced.
Readers should treat statements about rapid expansion into liver trials as the research team’s stated intent rather than confirmed regulatory milestones.
The treatment landscape has a gap
To understand why a generic inhaler drug is generating this level of interest, consider the competitive landscape. The FDA approved resmetirom, marketed as Rezdiffra, in March 2024 as the first-ever therapy for metabolic dysfunction-associated steatohepatitis (MASH), the advanced inflammatory stage of fatty liver disease. It was a landmark moment for a condition that had relied entirely on lifestyle changes and off-label use of diabetes or lipid drugs.
But that landmark was short-lived. Manufacturer Madrigal Pharmaceuticals voluntarily withdrew Rezdiffra from the U.S. market in April 2025, citing commercial challenges. The withdrawal left MASH patients, once again, without a dedicated approved therapy. That vacuum makes any credible new candidate more urgent, and formoterol’s decades-long safety record in respiratory patients, combined with its low cost as a generic, makes it an unusually practical one, if the biology cooperates.
A genuine scientific contradiction needs resolving
Before enthusiasm runs too far ahead of the data, there is a complication that deserves attention. Earlier rodent research published in the Journal of Endocrinology found that beta-2 adrenergic receptor agonism, the same pharmacological mechanism formoterol uses, actually induced hepatic steatosis in mice under hyperadrenergic conditions. That study reported gene expression changes in lipid droplet-associated proteins and reduced hepatic glycogen, both signs of worsening liver fat metabolism.
In plain terms: the same class of drug that cleared fat from the liver in one experiment appeared to cause fat buildup in another.
The contradiction likely comes down to context. Mice in a hyperadrenergic state, where stress hormones are already elevated, may respond to additional beta-2 stimulation very differently than obese mice on a high-fat diet without that hormonal backdrop. Differences in dose, duration, strain, and diet composition could all shape the outcome. But the tension is not academic. Patients with fatty liver disease frequently have elevated sympathetic nervous system activity tied to obesity, diabetes, or metabolic syndrome. Choosing the wrong dose or patient profile could, in theory, worsen the condition the drug is meant to treat.
The newer MUSC findings do not directly address or reconcile this conflict in their published text. Resolving it will be essential before any large-scale human trial moves forward.
Open questions that will shape what comes next
Several practical unknowns stand between the mouse data and a viable human therapy:
- Delivery route: It is unclear whether inhaled formoterol at standard respiratory doses delivers enough drug systemically to affect liver tissue, or whether oral or intravenous dosing would be required. The mouse studies used regimens that may not translate directly to inhaler use.
- Cardiovascular safety: Beta-2 agonists can influence heart rate, blood pressure, and arrhythmia risk. Many fatty liver patients already carry cardiovascular risk factors, and long-term formoterol exposure in this population has not been studied.
- Steatosis vs. MASH vs. fibrosis: The mouse work demonstrated reversal of steatosis (fat accumulation). Whether formoterol can also reduce inflammation or fibrosis, the features that make MASH dangerous, is unknown.
- Dosing and duration: Four weeks reversed steatosis in mice. The equivalent human treatment course, and whether benefits persist after stopping the drug, remain open questions.
None of these parameters have been systematically tested in people with fatty liver disease using formoterol as a metabolic therapy.
Where this stands in May 2026
The evidence chain so far runs from two peer-reviewed mouse studies, one showing kidney benefit and one showing liver benefit, into a registered human pilot trial for the kidney indication. Each link is documented in public, verifiable records. The npj Metabolic Health and Disease paper provides histology scores, lipid measurements, and mitochondrial markers that together suggest genuine reversal of steatosis, not just a modest slowing of progression. The American Journal of Physiology paper shows formoterol can remodel diseased tissue in at least one organ system. And the ClinicalTrials.gov listing confirms that human testing of formoterol in a metabolic context is active.
What does not yet exist: a registered liver-specific trial, published human dosing data for this indication, or any regulatory filing that would signal an imminent MASH study. The scientific case for exploring one is growing stronger, but formoterol’s role in fatty liver disease remains an intriguing, early-stage possibility, not an imminent treatment. For the roughly 100 million Americans living with some form of the disease, the honest answer is that this is worth watching closely, but not worth changing any medical decisions over today.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
